The Wolverine Stack or BPC-157 on its own?

What each peptide is

BPC-157 is a synthetic peptide based on a fragment of a protein found in stomach juice. The U.S. Anti-Doping Agency describes it as not approved for human clinical use by the FDA or any other health authority. Much of its research is in animal models of gut inflammation and soft-tissue injury.

TB-500 is where naming gets confusing. The FDA defines TB-500 as a short fragment of thymosin beta-4 (the sequence LKKTETQ), while some anti-doping bodies use TB-500 as another name for the full 43-amino-acid thymosin beta-4 protein. The full protein has been tested in early clinical studies for wounds, eye injuries and heart conditions. The short fragment has no published controlled human trials, and the FDA says it has identified no human exposure data for products containing it.

The theory behind stacking

In laboratory and animal studies, BPC-157 has been linked to new blood vessel growth, nitric oxide signaling and reduced inflammatory markers. Thymosin beta-4 is involved in cell migration and the actin scaffolding cells use to move and repair. The stack's logic is that these complementary actions could add up.

That is a hypothesis. Mechanisms seen in rodents or cell cultures often fail to translate to people, and two mechanisms do not automatically add together.

What has actually been tested

• BPC-157: a 2025 systematic review in HSS Journal found 36 studies, 35 preclinical and one clinical, a retrospective series of 12 people with knee pain given injections, in which 7 reported improvement. The authors urged caution and called for proper trials.
• TB-500 fragment: no published controlled human trials.
• The combination: no published study of any kind comparing the stack with either peptide alone.
• Long-term safety: no human data for either peptide; animal data on BPC-157 extend to about six weeks.

Where both stand with the FDA

Neither peptide is FDA-approved. Both were previously in Category 2 of the FDA's interim lists for compounding bulk substances, the group with significant safety concerns. The FDA's page now lists both among substances whose nominations were withdrawn, while still describing concerns: possible immune reactions from peptide impurities for certain routes, and too little information to know whether they would harm people.

At its July 23, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157 for ulcerative colitis and TB-500 for wound healing, and voted in favor of adding both to the 503A bulks list. Committee votes are advisory. The FDA makes the final decision, and formal listing requires rulemaking, so the status may change. HealifyMD only arranges a prescription when a licensed pharmacy confirms it can dispense the product under current federal and state rules.

The honest comparison

• Evidence: BPC-157 alone has a little more research behind it, though still mostly animal. The stack adds a peptide with even less human data.
• Unknowns: two peptides means two sets of possible impurities, immune reactions and interactions, with no data on how they behave together.
• Interpretation: if you feel better on the stack, you cannot tell which peptide, if either, helped.
• Cost: the Wolverine Stack is from $350/month and BPC-157 alone is from $250/month, confirmed at the eligibility review.
• Sport: BPC-157 is prohibited under WADA's non-approved substances category, and thymosin beta-4 is prohibited at all times as a growth factor modulator.

Who should avoid both

Because these peptides are thought to promote new blood vessel growth and cell proliferation, people with active cancer or a history of cancer should not use them; Sport Integrity Australia specifically flags concern that thymosin beta-4 could promote cancer growth. They are also not for pregnancy or breastfeeding, anyone under 18 or tested athletes.

An injury that is not healing deserves a diagnosis first. Imaging, physical therapy and a sports medicine or orthopedic opinion should come before experimental peptides, and a peptide should never replace them.

How HealifyMD approaches it

Your clinician will usually favor the simplest option: proven care for the injury, and if a peptide is considered at all, one rather than two, so its effect can be judged. Both products are compounded by a licensed U.S. pharmacy, are not FDA-approved, have not been reviewed by the FDA for safety, effectiveness or quality and are not equivalent to any approved drug. Dosing is set by your clinician; we do not publish home dosing schedules.